T2 Biosystems, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-04-07: Form 8-K; Period of report 2025-03-18; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2025-02-20: Form 8-K; Period of report 2025-02-20; Description 8.01 Other Events; Details 8.01.
- 2025-02-14: Form 8-K; Period of report 2025-02-13; Description 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events; Details 2.05.
- 2025-02-11: Form 8-K; Period of report 2025-02-10; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2025-04-07 | 8-K | 2025-03-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 31, 2025, John Sperzel and Robin Toft each notified T2 Biosystems, Inc. (the “Company”) of their respective resignations as members of the Company’s board of directors (the “Board”) and all committees thereof, effective immediately. | d919843d8k.htm |
| 2025-02-20 | 8-K | 2025-02-20 | 8.01 Other Events | 8.01 As previously disclosed, on February 13, 2025 the Board of Directors (the “Board”) of T2 Biosystems, Inc. (the “Company’”) approved a reduction-in-force of substantially all of its employees, effective immediately. | d935844d8k.htm |
| 2025-02-14 | 8-K | 2025-02-13 | 2.05 Costs Associated with Exit or Disposal Activities; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 2.05 On February 13, 2025, the Board of Directors (the “Board”) of T2 Biosystems, Inc. (the “Company”) approved a reduction-in-force (the “Reduction-in-Force”) of substantially all of its employees, effective immediately (the “Effective Time”). 5.02 In connection with the actions discussed in Item 2.05 above, John Sperzel, President and Chief Executive Officer, John Sprague, Chief Financial Officer, and Michael Gibbs, Senior Vice President and General Counsel, were terminated without cause from their respective positions, effective immediately. 8.01 The Company previously disclosed that it intended to hold a Special Meeting of Stockholders (the “Special Meeting”) on March 3, 2025 to approve an amendment to the Company’s certificate of incorporation to effect a reverse stock split of the Company’s common stock in order to regain compliance with the bid price requirement of Nasdaq Listing Rule 5550(a)(2). | d926272d8k.htm |
| 2025-02-11 | 8-K | 2025-02-10 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On February 10, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified T2 Biosystems, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s common stock and that trading of the Company’s common stock will be suspended at the open of trading on February 12, 2025. | d869925d8k.htm |
| 2025-01-17 | 8-K | 2025-01-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d925440d8k.htm |
| 2025-01-07 | 8-K | 2025-01-07 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On January 7, 2025, the Company issued a press release announcing its financial results for its fiscal quarter and full year ended December 31, 2024. 8.01 • Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales. | d885819d8k.htm |
| 2025-01-03 | 8-K | 2024-12-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 T2 Biosystems, Inc. (the “Company’”) held its annual meeting of stockholders on December 30, 2024 (the “Annual Meeting”). 5.07 At the Annual Meeting, stockholders holding and entitled to vote 15,810,290 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) held as of the close of business on November 5, 2024 (the “Record Date”) were present either by attendance via live webcast or by proxy. | d919156d8k.htm |